Retrospective Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2017; 23(43): 7735-7745
Published online Nov 21, 2017. doi: 10.3748/wjg.v23.i43.7735
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus
Zi-Han Zhang, Qing-Xin Liu, Wen Zhang, Jing-Qin Ma, Jian-Hua Wang, Jian-Jun Luo, Ling-Xiao Liu, Zhi-Ping Yan
Zi-Han Zhang, Qing-Xin Liu, Wen Zhang, Jing-Qin Ma, Jian-Hua Wang, Jian-Jun Luo, Ling-Xiao Liu, Zhi-Ping Yan, Department of Interventional Radiology, Zhongshan Hospital, Fudan University and Shanghai Institute of Medical Imaging, Shanghai 20032, China.
Author contributions: Ma JQ, Luo JJ and Yan ZP were involved in study conception and design; Zhang ZH and Zhang W acquired the data; Liu QX, Wang JH, and Liu LX analyzed and interpreted the data; All authors were involved in the drafting and critical revision of the manuscript and approved the final version of the manuscript.
Supported by the Project of Advanced and Appropriate Technique Generalization of Shanghai Health and Family Planning Committee, No. 2013SY060; and the Scientific Program of Shanghai Municipal Heath Bureau, No. 20124188.
Institutional review board statement: The study protocol was reviewed and approved by the institutional ethics committee of the respective hospital involved.
Conflict-of-interest statement: The authors have no conflict of interest to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author, Dr. Jian-Jun Luo, at zsluojianjun@126.com.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jian-Jun Luo, MD, Department of Interventional Radiology, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai 20032, China. zsluojianjun@126.com
Telephone: +86-13801924777
Received: August 17, 2017
Peer-review started: August 18, 2017
First decision: August 30, 2017
Revised: September 18, 2017
Accepted: October 17, 2017
Article in press: October 17, 2017
Published online: November 21, 2017
Processing time: 94 Days and 16.6 Hours
Abstract
AIM

To evaluate the safety and efficacy of combined endovascular brachytherapy (EVBT), transarterial chemoembolization (TACE), and sorafenib to treat hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus (MPVTT).

METHODS

This single-center retrospective study involved 68 patients with unresectable HCC or those who were unfit for liver transplantation and percutaneous frequency ablation according to the BCLC classification. All patients had Child-Pugh classification grade A or B, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and MPVTT. The patients received either EVBT with stent placement, TACE, and sorafenib (group A, n = 37), or TACE with sorafenib (group B, n = 31). The time to progression (TTP) and overall survival (OS) were evaluated by propensity score analysis.

RESULTS

In the entire cohort, the 6-, 12-, and 24-mo survival rates were 88.9%, 54.3%, and 14.1% in group A, and 45.8%, 0%, and 0% in group B, respectively (P < 0.001). The median TTP and OS were significantly longer in group A than group B (TTP: 9.0 mo vs 3.4 mo, P < 0.001; OS: 12.3 mo vs 5.2 mo, P < 0.001). In the propensity score-matched cohort, the median OS was longer in group A than in group B (10.3 mo vs 6.0 mo, P < 0.001). Similarly, the median TTP was longer in group A than in group B (9.0 mo vs 3.4 mo, P < 0.001). Multivariate Cox analysis revealed that the EVBT combined with stent placement, TACE, and sorafenib strategy was an independent predictor of favorable OS (HR = 0.18, P < 0.001).

CONCLUSION

EVBT combined with stent placement, TACE, and sorafenib might be a safe and effective palliative treatment option for MPVTT.

Keywords: Hepatocellular carcinoma; Transarterial chemoembolization; Endovascular brachytherapy; Main portal vein tumor thrombus; Sorafenib

Core tip: As portal vein tumor thrombus occurs in a high proportion of hepatocellular carcinoma patients and no standard treatment has been established, we aimed to evaluate the effect of endovascular brachytherapy (EVBT) combined with stent placement, transarterial chemoembolization (TACE), and sorafenib and compared this strategy with TACE plus sorafenib alone. The results of our study revealed that EVBT along with stent placement, TACE, and sorafenib is a safe and effective palliative treatment option for main portal vein tumor thrombus.